LLY vs MDLN
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. MDLN: Medline is a global healthcare products and services distributor supplying hospitals, clinics, and other healthcare settings with medical supplies, equipment, and solutions.
Side-by-side fundamentals
| Metric | LLY | MDLN | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $1,156.63 | $39.44 | |
| Market cap as of 2026-07-16 | $1.07T | $51.8B | |
| P/E as of 2026-07-16 | 42.43 | 53.64 | LLY lower |
| PEG as of 2026-07-16 | 1.37 | 11.46 | LLY lower |
| Net margin as of 2026-07-16 | +35.0% | +3.3% | LLY higher |
| Gross margin as of 2026-07-16 | +82.8% | +25.9% | LLY higher |
| Operating margin as of 2026-07-16 | +43.6% | +7.1% | LLY higher |
| ROE as of 2026-07-16 | +101.3% | +6.9% | LLY higher |
| ROA as of 2026-07-16 | +22.7% | +2.6% | LLY higher |
| Debt / equity as of 2026-07-16 | 1.39 | 1.12 | MDLN lower |
| Revenue growth (YoY) as of 2026-07-16 | +47.4% | +10.7% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +10.6% | LLY higher |
| Dividend yield as of 2026-07-16 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-16 | 0.50 | 1.12 | |
| 1-year return as of 2026-07-15 close | +49.9% | -8.0% | LLY higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.